How is the trial being organised?
The E-CLAD UK trial will recruit a total of 90 double lung transplant patients with CLAD from across all 5 adult lung transplant centres in the UK (Newcastle, Birmingham, London (Harefield), Cambridge and Manchester). Patients who have had a single lung transplant or are currently awaiting re-transplant will not be eligible to take part. Other inclusion and exclusion criteria will also apply for the trial.
Patients interested in finding out further information on the E-CLAD UK trial and what is involved should read our Introductory Information Sheet.
Introductory Patient Information Sheet PDF 255Kb
Patients who are suitable to take part and give their consent will be randomly allocated to one of two groups. One group will receive the current usual treatment for CLAD and the other group will receive ECP treatment in addition to the current usual treatment.
ECP treatment will involve a course of up to 9 ECP cycles over a 20-week period. Each cycle consists of 2 individual treatments given on consecutive days and lasting 2-3 hours each. All participants will be closely monitored for any changes to lung function during the trial.
ECP treatment can make the whole body more sensitive to sunlight. To find out more about protecting yourself after ECP treatment read our UV guidance document.
ECP UV guidance PDF 243Kb
Recruitment to the trial is due to run until June 2025, with the last patient visit expected to take place in December 2025.
This project is sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust and funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership (ref NIHR130612). The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR or the Department of Health and Social Care.